Report Overview

The increasing adoption of technological advancements, a growing focus on effectively managing chronic ailments and remote surveillance are projected to propel the expansion of the United States connected drug delivery devices market during the forecast period between 2023 and 2029.

United States Connected Drug Delivery Devices Market - Industry Trends & Forecast Report, 2029

United States connected drug delivery devices market size was estimated at USD 375.74 million in 2022. During the forecast period between 2023 and 2029, the size of United States connected drug delivery devices market is projected to grow at a CAGR of 11.25% reaching a value of USD 792.48 million by 2029. Major growth drivers for the United States connected drug delivery devices market include an increasing demand to enhance patient medication adherence, alongside a rising trend in research and development activities. This surge in activity is fueling exponential growth, thanks to the robust product pipeline from key players primed for commercial release during the forecast period. Further driving the market is the imperative to enhance patient medication adherence. As the call for connected drug delivery devices escalates, patients gain the ability to efficiently self-manage their treatment, leading to decreased clinic and hospital visits. These devices not only ensure precise dosage administration but also diminish the need for costly secondary interventions. Particularly in conditions like asthma and COPD, these devices play a vital role in patient care. By offering reminders and adherence tracking, they facilitate patient compliance with prescribed medication regimens, thereby mitigating the waste of valuable medications like injectable biologics. This synergy of factors is propelling the United States connected drug delivery devices market toward substantial growth.

United States Connected Drug Delivery Devices Market – Overview

United States connected drug delivery devices market pertains to the sector within the United States healthcare industry that encompasses the production, distribution, and utilization of advanced drug delivery devices integrated with connectivity features. These devices are designed to facilitate enhanced medication adherence and patient self-management through digital monitoring and communication capabilities. The market's growth is driven by factors such as the need to improve patient compliance, advancements in research and development, and the accelerated adoption of remote monitoring, influenced by the COVID-19 pandemic. Connected drug delivery devices enable patients to receive accurate dosages, timely reminders, and adherence tracking, ultimately contributing to better treatment outcomes and reduced healthcare costs. This market's evolution signifies the intersection of medical technology and patient-centric care in modern healthcare practices across the United States.

United States Connected Drug Delivery Devices Market

Growth Drivers

Increasing Prevalence of Chronic Diseases

Connected drug delivery systems facilitate healthcare professionals in monitoring patient progress, assessing treatment efficacy, and making necessary adjustments to care plans. For example, individuals with chronic conditions like diabetes and asthma can benefit from these devices for self-medication management. The Asthma and Allergy Foundation of America reports that approximately 20 million adults, both under and over 18 years old, are afflicted with asthma in the United States. Notably, 9.8% of female adults and 6.1% of male adults are affected. These dynamics are expected to propel growth in the United States connected drug delivery devices market throughout the forecast period.

Restraints

Data Privacy and Security

United States connected drug delivery devices market growth is hindered by data privacy and security concerns. These concerns arise due to potential breaches of sensitive patient health data, cybersecurity risks, regulatory compliance challenges, and legal liabilities. Patient confidentiality and trust are at stake, impacting adoption rates. Stricter healthcare regulations like HIPAA add complexity. Healthcare providers might hesitate due to uncertainties about data security. To overcome these obstacles and encourage growth, robust data encryption, transparent practices, and emphasizing benefits while addressing security risks are pivotal. Balancing technological advancements with data protection is crucial for fostering trust, adoption, and market expansion.

Impact of COVID-19 on United States Connected Drug Delivery Devices Market

COVID-19 pandemic had a positive impact on the United States connected drug delivery devices market due to the increased awareness of these devices and the fostering of their adoption by both healthcare providers and patients. The significance of remote monitoring for medication adherence gained prominence as the pandemic underscored the value of minimizing in-person interactions. For instance, in 2021, Adherium Limited, a leading respiratory eHealth company, witnessed a global upswing in remote patient monitoring due to the pandemic. However, the company encountered pandemic-related challenges in executing planned pilot evaluations with partners in the United States. Looking back to 2022, the company expected robust commercial and research activities as movement restrictions eased and hospital access improved. This dynamic blend of challenges and opportunities in the post-pandemic landscape influenced the market's trajectory.

United States Connected Drug Delivery Devices Market

Segmental Coverage

United States Connected Drug Delivery Devices Market – By Type

By type, the United States connected drug delivery devices market is split into Injectable Devices and Inhalation Devices & Others segments. The injectable devices segment held a higher marker share by type. Injectable drug delivery is commonly used for various medical conditions, especially chronic diseases requiring accurate dosing. The integration of connectivity enhances precision and patient compliance, crucial for effective treatment outcomes. In critical care and complex interventions, real-time monitoring and adjustment are essential, which connected injectable devices facilitate. Healthcare providers can remotely monitor patients and make timely modifications. This segment's dominance stems from its ability to address modern medical demands effectively, driving its prominence in the US connected drug delivery devices market.

United States Connected Drug Delivery Devices Market – By Technology

Based on technology, the United States connected drug delivery devices market is split into Bluetooth and NFC (Near Field Communication) segments. Bluetooth technology offers seamless and secure wireless communication, allowing devices to connect and exchange data with minimal interference. This feature is particularly vital in healthcare settings where data accuracy and privacy are paramount. Bluetooth-enabled devices enable real-time monitoring, data transmission, and remote control, enhancing patient care and treatment management. Furthermore, the widespread use of smartphones and tablets with built-in Bluetooth capabilities facilitates user-friendly interactions. The established compatibility of Bluetooth technology with various devices and its proven reliability have contributed to its dominance within the United States connected drug delivery devices market, making it the preferred choice for ensuring efficient and effective connected healthcare solutions.

United States Connected Drug Delivery Devices Market – By End User

Based on end user, the United States connected drug delivery devices market is divided into Homecare Settings and Hospitals segments. The homecare settings held a higher share in the United States connected drug delivery devices market by end user. Patients prefer the comfort and convenience of homecare, and connected drug delivery devices enable them to manage treatments independently while staying connected to healthcare providers remotely. This is especially valuable for chronic condition management. The COVID-19 pandemic further emphasized the significance of minimizing hospital visits, driving the adoption of connected devices for home-based care. The rising popularity of telehealth and remote monitoring also aligns with the suitability of connected drug delivery devices for homecare. As patients increasingly seek personalized, convenient, and safe healthcare solutions, the homecare settings segment continues to dominate the market.

Competitive Landscape

Major players operating in the United States connected drug delivery devices market include Propeller Health, Adherium, Teva Pharmaceutical Industries, Novartis, AstraZeneca, GSK (GlaxoSmithKline), Boehringer Ingelheim, ResMed, Amgen, and Becton, Dickinson and Company (BD). To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

• In September 2022  - Nemera unveiled a novel establishment in Lyon, France, anticipated to serve as the company's fresh European headquarters and innovation hub.

Scope of the Report

By Type

• Injectable Devices

• Inhalation Devices and Others

By Technology

• Bluetooth

• NFC (Near Field Communication)

By End User

• Homecare Settings

• Hospitals